Clinical Trial Update: Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies [Phase 2]

View source ↗

Summary

This Phase 2 trial studied the combination of lenalidomide and ipilimumab after stem cell transplantation in patients with hematologic or lymphoid malignancies.…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma
• Hematologic Malignancies
• Leukemia
• Lymphoma
• Multiple Myeloma
• T-cell Non-hodgkin Lymphoma

Drugs mentioned

• Revlimid (lenalidomide)
• Yervoy (ipilimumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: B-Cell Non-Hodgkin Lymphoma, Hematopoietic and Lymphoid Cell Neoplasm | Phase 2 | Status: COMPLETED | Results posted: 2024-12-03